Chia Tai Tianqing Pharmaceutical Group
Subsidiary of Sino Biopharmaceutical (1177) · China
Assets
(3 total)
3Total Assets
1Approved
1Phase 3 / Filed
1Phase 1–2 / Early
6Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | PD-1Monoclonal antibody | Non-Small Cell Lung CancerHepatocellular CarcinomaNasopharyngeal Carcinoma | |
| Phase 3 | Peroxisome proliferator-activated receptors (PPARs) · PPAR (pan-agonist)Small molecule | Type 2 DiabetesMASH / NASH | |
| Phase 2 | TSLPMonoclonal antibody | Atopic Dermatitis |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
No financial reports recorded.